CVRx (Nasdaq:CVRX) announced the publication of post-market data highlighting long-term, sustained benefits with its Barostim device. Minneapolis-based CVRx published results from the BeAT-HF trial in the European Journal of Heart Failure. Data supported Barostim treatment in heart failure patients with reduced ejection fraction. Barostim delivers electrical pulses to baroreceptors in the wall of the carotid […]
cvrx
Augmedics CEO is taking over corner office at CVRx
CVRx (Nasdaq:CVRX) announced today that it appointed Kevin Hykes as its new president and CEO, effective Feb. 12. Hykes already has familiarity with the Minneapolis-based neurostimulation technology developer, having joined its board in December 2022. He will continue to serve on the board, with CEO Nadim Yared set to retire from the company and resign […]
CVRx stock dips despite Street-beating Q4
CVRx (Nasdaq:CVRX) shares took a hit today despite fourth-quarter results that beat the consensus forecast. Shares of CVRx fell 5.2% at $27.69 apiece in mid-afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.2%. The Minneapolis-based neuromodulation technology developer posted losses of $9.2 million. […]
FDA approves expanded label for CVRx neuromod tech
CVRx (Nasdaq:CVRX) announced today that it received FDA approval for revised instructions for use for its Barostim neuromodulation system. The new instructions for use incorporate key long-term data from the Minneapolis-based company’s BeAT-HF randomized clinical trial. CVRx designed Barostim to deliver electrical pulses to baroreceptors in the wall of the carotid artery. These activate the […]
Study backs CVRx Barostim neuromod for patients with heart failure
Data presented today supported the use of the Barostim neuromodulation device from CVRx (Nasdaq:CVRX) in patients with cardiovascular diseases. The BeAT-HF trial evaluated the Barostim extravascular, implantable neuromodulation device. Dr. Michael Zile, professor of cardiology at the Medical University of South Carolina, presented findings at the second annual Technology and Heart Failure (HF) Therapeutics (THT) […]
CVRx stock up on Street-beating Q2 sales, raised guidance
CVRx (Nasdaq:CVRX) shares were up this morning on second-quarter results that beat the consensus revenue forecast. The Minneapolis-based neuromodulation technology developer posted losses of $11.1 million, or 54¢ per share, on sales of just over $5 million for the three months ended June 30, 2022, for a more than $6 million bottom-line gain despite remaining […]
CVRx launches new Barostim programmer in U.S.
CVRx (Nasdaq:CVRX) announced that it launched its new Barostim programmer following its approval by the FDA earlier this year. Minneapolis-based CVRx designed its second-generation programmer to operate on an upgraded cellular network to enable remote view access. It also includes an improved user interface that simplifies implantable pulse generator (IPG) programming. According to a news […]
FDA approves magnetic resonance labeling for CVRx’s Barostim neuromodulation system
CVRx (Nasdaq:CVRX) announced today that the FDA approved magnetic resonance (MR) conditional labeling for its Barostim system. The Barostim neuromodulation system for treating the symptoms of heart failure now includes instructions to allow for safe MRI scans of the head and lower extremities, offering heart failure patients implanted with Barostim more diagnostic options. Minneapolis-based CVRx […]
CVRx misses in Q4, wins FDA approval for new IPG
CVRx (NSDQ:CVRX) posted fourth-quarter results today that fell short of the consensus forecast on Wall Street and offered its outlook for the year ahead. The Brooklyn Park, Minnesota–based neuromodulation implant developer reported a loss of $10.57 million, or $0.52 per diluted share, on sales of $3.7 million for the three months ended Dec. 31, 2021, […]
The 18 most innovative medical devices of 2021
The Galien Foundation today announced the nominees for most innovative medical devices for its 15th annual Prix Galien USA Awards. The foundation nominates devices, biotechnology and pharmaceutical products for its annual Prix Galien awards to highlight products designed to improve the human condition. “The Awards Committee is excited to introduce the nominees for the 2021 […]